“New figures released by the NHS show that more than 10,600 lung cancers have been identified through the Lung Cancer Screening Programme since it began in 2019. Over three-quarters of those cases were detected at stage one or stage two, when treatment is far more likely to be successful.”
Silencing of NUP62 overcomes osimertinib resistance via ubiquitination of survivin in non-small cell lung cancer cells
“Conclusion: NUP62 knockdown reverses OSI resistance by promoting ubiquitination of survivin in OSI-resistant NSCLC cell lines. Silencing of NUP62 may, therefore, be an effective strategy to overcome OSI resistance and enhance therapeutic efficacy.”
Ivonescimab May Improve Overall Survival in Patients With Advanced Squamous Non-Small Cell Lung Cancer
““This is the first large prospective trial to prove that an anti-PD-1/VEGF bispecific therapy plus chemotherapy is superior to the established standard of PD‑1 inhibitor plus chemotherapy in patients with advanced squamous lung cancer. While this study included participants from China and efficacy data from global populations are pending, it provides a vital new path forward for patients with these difficult-to-treat cancers who have limited treatment options,” said David R. Spigel, MD, FASCO, President and Chief Medical Officer at Sarah Cannon Research Institute and an ASCO Expert in lung cancer.”
Lung cancer cells switch identity to resist treatment
“Research published today [27 May] in Molecular Oncology reveals how lung cancer cells can become more aggressive and harder to treat by reactivating a process involved in early lung development.”
Evaluation of Lung Cancer Probability Models and Guideline Recommendations in Settings With a High Prevalence of Cancer
“When doctors find a pulmonary nodule, which is a small spot in the lung, they often try to estimate the chance that it is cancer before deciding on the next test or treatment. This study looked at how well four commonly used prediction models—the Mayo, Brock, Veterans Affairs (VA), and Peking University (PKU) models—worked in a setting where lung cancer was very common.”
Five things governments can do to turn the tide on lung cancer
“Lung cancer is the world’s biggest cancer killer. In the WHO European Region in 2021, it claimed 444,900 lives, cost societies €233 billion, and accounted for 10 million healthy years of life lost. Behind every number is a patient who deserved better: an earlier diagnosis, access to treatment while the disease was still more treatable, and a care pathway designed with them in mind. This must, and can, change. Here are five critical actions governments can take to reduce the burden and societal impact of lung cancer.”
AI could clear a path for precision medicine in lung cancer
“‘Tissue is the issue’ is a well-known phrase in the lung cancer field. Even while precision medicine transforms treatment, progress is constrained by a fundamental challenge: the limited tissue available for the genetic and molecular testing that guides a targeted response.”
Never smoked? Good, but you could still get lung cancer
“Lung cancer in people who have never smoked is now recognized as a distinct disease with its own treatments and preventative strategies.”
FDA Grants Priority Review to Neladalkib NDA for ALK-Positive NSCLC
“Key Takeaways: Priority review was granted for neladalkib in TKI-pretreated advanced ALK-positive NSCLC, reflecting a regulatory timeline culminating in a November 27, 2026, PDUFA action date. ALKOVE-1 (phase 1/2) provides the clinical foundation, enrolling ALK-positive NSCLC and other ALK-altered solid tumors after prior TKI therapy, with expanded adolescent and pediatric cohorts.”
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
“First Breakthrough Therapy designation for calderasib, supported by positive data from the Phase 1 KANDLELIT-001 trial. Calderasib is an investigational, highly potent and specific next-generation KRAS G12C covalent inhibitor.”
Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
“Patients had a 55% likelihood of remaining alive without disease progression at seven years, and median progression-free survival was not reached with LORBRENA. Updated follow-up analysis solidifies LORBRENA as a preferred standard of care, building upon five-year results.”
Lung cancer patients who smoke and don’t quit before surgery still have positive outcomes, says study
“Researchers at the University of Cincinnati College of Medicine have found that patients who continue to smoke ahead of lung cancer surgery have a higher risk of pulmonary complications, but their short-term mortality rate is similar to patients who were able to stop smoking before surgery.”
Targeted therapy reduces risk of lung cancer recurrence by 83% in rare genetic subtype
“The international phase 3 clinical trial, called LIBRETTO-432, found that after two years, 92% of patients with stage II–IIIA RET fusion-positive NSCLC who received selpercatinib after standard treatment were alive without their cancer returning — a measure known as event-free survival — compared with 61% of patients who received a placebo. Overall, the treatment reduced the risk of cancer recurrence or death by 83%.”
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
“Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson’s RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease. Consistent responses observed across atypical EGFR mutation subgroups, including those historically associated with poorer outcomes. ASCO 2026 results reinforce the significance of RYBREVANT®-based regimens for patients across EGFR mutations.”
